Low-Dose Naltrexone for Cancer Pain: Dosing, Evidence, and Safety with Chemotherapy and Hormonal Therapies
What is low-dose naltrexone?
Naltrexone is an FDA-approved medication. At a standard dose of 50 mg per day, naltrexone treats alcohol and opioid use disorders, as outlined in a published review of LDN therapeutic applications. At much lower doses – between 1.5 mg and 4.5 mg per day – it works differently in the body. These doses are called low-dose naltrexone, or LDN. Researchers and clinicians have been studying LDN off-label for chronic pain, autoimmune conditions, and more recently for cancer-related pain and as a possible add-on in cancer care.
Many people with breast cancer experience pain. It can come from the cancer itself, from surgery, from chemotherapy-related nerve damage, or from joint stiffness and muscle aches that often occur with hormonal therapies such as tamoxifen and aromatase inhibitors. LDN is not an FDA-approved cancer therapy. However, early research has led integrative oncology clinicians to consider it as a possible pain management option and as an adjuvant – an add-on treatment – alongside standard care. All evidence described below is preliminary. LDN should only be considered under the guidance of a qualified clinician.
| Axis | LDN with Chemotherapy | LDN with Hormonal Therapy |
|---|---|---|
| Typical dose studied | 1.5-4.5 mg daily; most common: 3.0 mg daily | 1.5-4.5 mg daily |
| Human evidence | One small randomized trial in glioma (110 patients); multiple preclinical studies across cancer types | One small uncontrolled trial in ER-positive breast cancer (8 patients); limited human data |
| Known drug interaction | No established interaction with most chemotherapy agents | No established interaction with tamoxifen or aromatase inhibitors |
| Use with opioid pain medicine | Not safe – LDN must be paused before opioid use | Not safe – LDN must be paused before opioid use |
| Regulatory status | Off-label; requires a compounding pharmacy | Off-label; requires a compounding pharmacy |
Dose range and patient figures sourced from Fiechter et al., Cancers, 2024 and a 2025 case series published in the Journal of Pain and Symptom Management.
How LDN may reduce pain
At the full 50 mg dose, naltrexone blocks opioid receptors around the clock. At low doses, that blockade lasts roughly 4 to 6 hours. When the blockade lifts, the body appears to compensate by producing more of its own natural opioids – including beta-endorphin and met-enkephalin. This rebound in natural opioid activity is one proposed reason LDN may reduce pain, as described in a 2023 scoping review on LDN and chronic pain conditions.
A second proposed mechanism involves the immune cells of the nervous system. Microglia are the primary immune cells of the brain and spinal cord. They carry a surface protein called Toll-like receptor 4, or TLR4. When TLR4 becomes active, microglia release inflammatory molecules – including TNF-alpha, IL-1 beta, and IL-6 – that can amplify pain signals. Research published in a 2021 study on naltrexone and microglia function found that naltrexone acts on TLR4, reducing this inflammatory response. Lowering this type of brain inflammation may help quiet overactive pain signals.
A third proposed mechanism involves a growth-controlling molecule called opioid growth factor, or OGF, and the cell receptor it binds to, called OGFr. OGF normally puts a brake on cell growth. A 2024 review published in Cancers explains that short-duration OGFr blockade by LDN prompts the body to produce more OGF, which may slow tumor cell growth. This is the basis for LDN’s possible role as an anti-cancer add-on, but researchers are still investigating.
What the clinical evidence shows
Cancer pain
A 2025 case series published in the Journal of Pain and Symptom Management examined LDN for refractory cancer-related pain – pain that standard treatments did not help. The most common maximum dose reached was 3.0 mg daily, with a range of 1.5 mg to 4.5 mg daily. Of 20 patients, 80% reported a positive response at the first follow-up visit. Among the 13 patients who reached a second follow-up, 76.9% maintained that positive response. Investigators described LDN as well-tolerated with a low rate of adverse events. These are early results, but the study was small and uncontrolled. They cannot yet support firm conclusions about LDN’s effectiveness for cancer pain.
Breast cancer
One small uncontrolled trial examined LDN in 8 people with estrogen receptor-positive (ER+) breast cancer. According to the 2024 review in Cancers, researchers found no evidence of an effect on disease progression in this group. The study was far too small to draw conclusions about efficacy or safety. No larger, controlled trials of LDN specifically in breast cancer have been completed. At present, doctors should not recommend LDN as an anti-tumor treatment for breast cancer outside of clinical trial settings.
Other cancer types
A randomized, placebo-controlled trial in 110 patients with high-grade glioma – a type of brain cancer – found that LDN produced an adverse event profile similar to placebo over 16 weeks. No serious adverse events occurred with LDN in that trial, according to data cited in the 2024 Cancers review. The trial contributed useful safety information, though its primary aim was not to assess cancer pain outcomes.
Typical dosing
LDN is not sold as a standard commercial product at these low doses. A compounding pharmacy must prepare LDN, which formulates the capsules or liquid to the exact prescribed strength. Based on published research, doctors typically start LDN at 1.5 mg taken once at night. The dose may increase gradually over several weeks up to a maximum of 4.5 mg per day. The most commonly used maintenance dose in cancer pain research was 3.0 mg daily, taken at bedtime.
Taking LDN at night is a common clinical practice. The reasoning is to align the short opioid-receptor blockade with the overnight period when the body’s natural opioid production already tends to rise. This timing approach has clinical support but no large randomized trials have confirmed this approach. Work with an integrative oncologist or palliative care specialist with experience in compounded medications to decide on your dose. If you are exploring this option, check Oncostore’s targeted-therapy options to review current compounded formulations and availability from a pharmacy familiar with integrative oncology needs.
Safety with chemotherapy
No established direct drug interactions exist between LDN and the chemotherapy agents most commonly used for breast cancer, such as anthracyclines, taxanes, and cyclophosphamide. The 2024 review in Cancers notes that LDN may show synergy with certain chemotherapy drugs in preclinical laboratory models, without appearing to harm healthy cells at the same time. These findings come from cell and animal studies, not from controlled human trials in breast cancer patients, so view them carefully.
Several practical considerations apply when adding any off-label agent to a chemotherapy regimen. Chemotherapy cycles often include rest periods and dose adjustments, and a patient’s ability to clear drugs can shift throughout treatment. Some chemotherapy agents cause nausea, vomiting, or gut lining irritation that may affect how well oral medications are absorbed. Tell your oncology team about every compounded or off-label medication before beginning a new chemotherapy cycle so they can monitor for unexpected effects.
Safety with hormonal therapy
Aromatase inhibitors and tamoxifen are standard treatments for hormone receptor-positive breast cancer. Patients most frequently report joint and muscle aches as side effects with these agents, and these aches often make patients consider stopping treatment early. Some integrative oncology clinicians have explored whether LDN might help manage this type of treatment-related pain, though researchers have limited formal data on this specific use.
Researchers have not found an established direct drug interaction between LDN and tamoxifen or aromatase inhibitors in the published literature. The body processes tamoxifen mainly through an enzyme called CYP2D6. The body clears LDN through a different metabolic route. These separate pathways reduce the chance of a direct metabolic clash. Even so, lack of a documented interaction doesn’t mean these drugs are safe together. Until adequately powered clinical trials address this question directly, clinicians should monitor patients carefully when they add LDN to a hormonal therapy regimen. Report any new or worsening symptoms to your prescribing team promptly.
The opioid interaction – the most critical safety concern
The most important safety issue with LDN in cancer care is its incompatibility with opioid pain medicines. Naltrexone blocks opioid receptors even at low doses. If someone is already taking an opioid such as oxycodone, morphine, hydromorphone, or fentanyl to manage cancer pain, taking LDN will block the effect of those opioids and can cause a sudden, severe withdrawal reaction.
Withdrawal symptoms may include rapid heart rate, sweating, nausea, vomiting, agitation, and a sharp spike in pain. This is a real risk. It means LDN is generally not suitable for patients whose cancer pain requires opioid medication. If a patient on LDN later needs emergency opioid pain control – for example, after a surgical procedure – you must stop LDN under medical supervision, and you must wait for naltrexone to clear your body before doctors can safely give you opioids. You and your doctor should make a clear written plan for this scenario before you start LDN.
Questions to ask your care team
- Is my current pain regimen opioid-based, or is LDN a compatible option for me?
- Does my oncologist or palliative care clinician have experience prescribing compounded LDN?
- Are there any clinical trials enrolling breast cancer patients for LDN research that I may qualify for?
- How will we measure whether LDN is helping, and what side effects should I watch for?
- What is the plan if I need opioid pain relief while on LDN – for example, after a procedure or surgery?
Where the research is heading
Integrative oncology researchers are studying LDN and several other repurposed medications. The early evidence shows pain relief in refractory cancer pain. The proposed mechanisms – reducing neuroinflammation through TLR4 and raising natural opioid levels – are biologically plausible and researchers are studying them. For breast cancer patients dealing with therapy-related joint pain or pain that standard treatments did not relieve, LDN might help. Consider discussing it with an integrative oncologist or palliative care clinician.
The field continues to develop. Readers who want to follow new LDN and integrative oncology research as researchers publish it can browse The Blog for updates on targeted therapies and evidence-based integrative approaches to cancer care.
If you are on prescription medication, pregnant, or breastfeeding, speak with your clinician before adding any compounded or off-label agent to your regimen. This article is for general information and does not replace medical advice. Always consult your oncologist or care team about your specific situation.
Frequently Asked Questions
What is the typical starting dose of LDN for cancer pain?
Most published studies and case reports start LDN at 1.5 mg taken once at bedtime. The dose is increased gradually over several weeks. The most commonly used maintenance dose in cancer pain research was 3.0 mg daily, and the highest dose studied was 4.5 mg per day. These low doses are not available in commercially manufactured tablets and must be prepared by a compounding pharmacy.
Can I use LDN if I am already taking opioid pain medication?
No. Naltrexone blocks opioid receptors even at low doses. Taking LDN alongside an opioid pain medicine such as oxycodone, morphine, or fentanyl can trigger a sudden withdrawal reaction that causes a sharp increase in pain, sweating, nausea, and agitation. LDN and opioid pain medicines must not be used at the same time without explicit medical supervision and a clear safety protocol in place.
Is LDN safe to take with tamoxifen or aromatase inhibitors?
No established direct drug interaction between LDN and tamoxifen or aromatase inhibitors has been identified in published research. Tamoxifen is processed through an enzyme called CYP2D6, and LDN is cleared through a different metabolic route. However, this specific combination has not been studied in adequately powered clinical trials. Anyone considering adding LDN to a hormonal therapy regimen should be closely monitored by their prescribing clinician.
Does LDN have proven anti-cancer effects in breast cancer?
The evidence is too limited to draw firm conclusions. One small uncontrolled trial in 8 people with ER-positive breast cancer found no effect on disease progression. Preclinical laboratory studies suggest LDN may slow tumor cell growth through the opioid growth factor receptor pathway, but these results have not been replicated in large human trials. LDN should not be used as a replacement for proven breast cancer treatments.
What side effects has LDN caused in cancer studies?
A 2025 case series of patients with refractory cancer pain reported that LDN was well-tolerated with a low rate of adverse events. A randomized trial in 110 glioma patients found no meaningful difference in adverse events between LDN and placebo over 16 weeks. The most commonly reported side effect in broader LDN research is vivid dreaming or mild sleep disruption, which often improves when the starting dose is kept low or the dose is taken a few hours before bedtime rather than at the time of sleep.
